ANI Pharmaceuticals, Inc. has signed an exclusive distribution and supply agreement with Aspen Global Inc. for Hydroxyprogesterone Caproate Injection (HPC) USP 250mg/mL in 5mL vials.  Aspen will be responsible for supplying the finished goods and ANI will be responsible for marketing and distribution in the U.S. Aspen’s product was approved by the FDA in August 2015 and ANI plans to commercialize HPC in the near term.
 
Arthur S. Przybyl, ANI’s president and chief executive officer said, “We are excited to enter into this exclusive strategic distribution partnership with Aspen and introduce to the U.S. market a product that addresses a high-need patient population.  We hope to build on the launches of HPC and our previously disclosed anti-cancer product (pending FDA approval, TAD June 2016) to strategically advance a portfolio of oncolytic products in the future.  Finally, this launch will also serve to establish ANI’s commercial presence in the specialty pharmacy distribution channel, one that we intend to build upon with future product introductions from our existing pipeline.”